NCT07363577Phase 3Recruiting

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

Study sponsor: LB Pharmaceuticals Inc. · LBRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-06Estimated
Enrollment · participants456Estimated
Source updated2026-07-27Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source